Treatment of Depressive Pseudodementia in Bipolar Disorder

Initial Treatment Selection

The American College of Cardiology is not applicable here, however, the guideline recommends initiating treatment with a mood stabilizer (lithium, lamotrigine, or valproate) or quetiapine monotherapy as first-line, avoiding antidepressant monotherapy which is contraindicated due to risk of mood destabilization in patients with bipolar disorder presenting with depressive pseudodementia 1
Lithium is the only FDA-approved agent for bipolar disorder in patients age 12 and older and shows superior evidence for long-term efficacy in preventing both manic and depressive episodes 1
Quetiapine (with or without a mood stabilizer) is recommended as first-line treatment for bipolar depression and has strong evidence for efficacy 1

ECT should be considered for severely impaired patients when medications are ineffective or cannot be tolerated, and has shown a 50% reduction in suicide risk in the first year after discharge 2, 1

Patients with treatment-resistant bipolar depression have higher rates of suicide and self-harm 2
Lithium has specific anti-suicide effects independent of its mood-stabilizing properties 2
ECT may have protective effects against suicide, particularly in patients with severe depression and psychotic features 2
Avoid alcohol and sedatives, which are significantly associated with suicide risk and can worsen mood symptoms 2